Shining light on Barrett's esophagus

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 577-580

  Quaroni, Luca ^a   Zhao, Ronghua ^b   Casson, Alan G ^b  

^a CANADIAN LIGHT SOURCE INC   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER RISK; CANCER STEM CELL; CIGARETTE SMOKING; DIAGNOSTIC VALUE; DIETARY INTAKE; DISEASE COURSE; EDITORIAL; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; HISTOPATHOLOGY; HUMAN; INFRARED SPECTROSCOPY; LIFESTYLE; MICROSCOPY; OBESITY; PRECANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; LIFE STYLE; OBESITY; RISK FACTORS; SMOKING; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 73449099302     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.43     Document Type: Editorial

References (37)

1. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 92(3), 151-159 (2005).
2. Vizcaino AP, Victor M, Rene L, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int. J. Cancer 99(6), 860-868 (2002).
3. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment. Pharmacol. Ther. 17(5), 665-676 (2003).
4. Brown LM, Devesa SS, Chow W-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J. Natl Cancer Inst. 100(16), 1184-1187 (2008). Most recent report of epidemiologic trends for esophageal malignancy in North America.
5. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340(11), 825-831 (1999). Seminal epidemiologic study that defines chronic gastroesophageal reflux disease (GERD) as a major risk factor for esophageal adenocarcinoma.
6. Forman D. Review article: oesophagogastric adenocarcinoma - an epidemiological perspective. Aliment. Pharmacol. Ther. 20(Suppl. 5), 55-60 (2004).
7. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin. Gastroenterol. Hepatol. 3(1), 1-10 (2005). Comprehensive review detailing the risk factors associated with esophageal adenocarcinoma.
8. Bird-Lieberman EL, Fitzgerald RC. Barrett's esophagus. Gastroenterol. Clinics N. Am. 37(4), 921-942 (2008).
9. Badreddine RJ, Wang KK. Barrett's esophagus: pathogenesis, treatment, and prevention. Gastrointest. Endosc. Clinics N. Am. 18(3), 495-512 (2008).
10. Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120(7), 1630-1639 (2001).
11. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am. J. Gastroenterol. 97(8), 1888-1895 (2002).
12. Shaheen NJ, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am. J. Gastroenterol. 97(6), 1319-1327 (2002).
13. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J. Clin. Pathol. 59(10), 1029-1038 (2006).
14. Koppert LB, Wijnhoven BPL, van Dekken H, Tilanus HW, Dinjens WNM. The molecular biology of esophageal adenocarcinoma. J. Surg. Oncol. 92(3), 169-190 (2005).
15. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55(12), 1810-1820 (2006).
16. Zhao R, Casson AG. Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer. Curr. Cancer Drug Targets 8, 509-521 (2008).
17. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15), 1972-1981 (2002). Overview of the associations between GERD, Barrett's esophagus (BE) and esophageal adenocarcinoma.
18. Casson AG, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect. Prevent. 30(5), 423-431 (2006).
19. Whiteman DC, Sadeghi S, Pandeya N et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 57(2), 173-180 (2008).
20. Vaninetti NM, Geldenhuys L, Porter GA et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol. Carcinogenesis 47(4), 275-285 (2008). Potential molecular basis underlying the association between GERD and the risk for BE and esophageal adenocarcinoma.
21. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surg. Clinics N. Am. 12(1), 93-111 (2002).
22. Chao DL, Sanchez CA, Galipeau PC et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin. Cancer Res. 14(21), 6988-6995 (2008).
23. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am. J. Gastroenterol. 96(11), 3071-3083 (2001). Flow cytometric criteria used to identify patients with BE at increased risk for progression to invasive esophageal adenocarcinoma.
24. Reid BJ, Prevo LJ, Galipeau PC et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96(10), 2839-2848 (2001).
25. Fernando HC, Murthy SC, Hofstetter W et al. The Society of Thoracic Surgeons Practice Guideline Series: guidelines for the management of Barrett's esophagus with high-grade dysplasia. Ann. Thorac. Surg. 87(6), 1993-2002 (2009).
26. Ellis DI, Harrigan GG, Goodacre R. Metabolic fingerprinting with Fourier transform infrared spectroscopy. In: Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis. Harrigan GG, Goodacre R (Eds). Kluwer Academic, Boston, MA, USA, 111-124 (2003).
27. Diem M, Griffiths PR, Chalmers JM. Vibrational Spectroscopy for Medical Diagnosis. Wiley, Chichester, West Sussex, UK (2008).
28. Heise HM. Infrared spectroscopy in medical diagnostics - recent developments in instrumentation and applications. VDI-Berichte 1667, 57-62 (2002).
29. Massaro S, Zlateva T, Torre V, Quaroni L. Detection of molecular processes in the intact retina by ATR-FTIR spectromicroscopy. Anal. Bioanal. Chem. 390(1), 317-322 (2008).
30. Wang TD, Triadafilopoulos G, Crawford JM et al. Detection of endogenous biomolecules in Barrett's esophagus by Fourier transform infrared spectroscopy. Proc. Natl Acad. Sci. USA 104(40), 15864-15869 (2007). Comprehensive study utilizing Fourier transform infrared spectroscopy (FTIR) to characterize BE.
31. Diem M, Romeo M, Boydston-White S, Miljkovic M, Matthaeus C. A decade of vibrational micro-spectroscopy of human cells and tissue (1994-2004). Analyst (Cambridge, UK) 129(10), 880-885 (2004).
32. Wong PTT, Senterman MK, Jackli P et al. Detailed account of confounding factors in interpretation of FTIR spectra of exfoliated cervical cells. Biopolymers 67(6), 376-386 (2002).
33. Quaroni L, Casson AG. Characterization of Barrett esophagus and esophageal adenocarcinoma by Fourier-transform infrared microscopy. Analyst (Cambridge, UK) 134(6), 1240-1246 (2009). Report of the use of FTIR spectromicroscopy to characterize esophageal tissues.
34. Krafft C, Sergo V. Biomedical applications of Raman and infrared spectroscopy to diagnose tissues. Spectroscopy (Amsterdam, Neth.) 20(5-6), 195-218 (2006).
35. Dumas P, Sockalingum GD, Sule-Suso J. Adding synchrotron radiation to infrared microspectroscopy: what's new in biomedical applications? Trends Biotechnol. 25(1), 40-44 (2007).
36. Sahu RK, Argov S, Salman A et al. Can Fourier transform infrared spectroscopy at higher wavenumbers (mid IR) shed light on biomarkers for carcinogenesis in tissues? J. Biomed. Opt. 10(5), 10(5), 054017 (2005).
37. Zhao R, Pedersen T, Quaroni L, Casson AG. Distinct mid-infrared spectra of stem-like cells in human esophageal epithelial and adenocarcinoma cells Proc. Annu. Meet. Am. Assoc. Cancer Res. 50, 1043 (2009). Preliminary report of the potential for synchrotron FTIR to characterize esophageal stem cell-like cell populations.